KAROLINSKA DEVELOPMENT AB Neuroinflammation is a complex process that occurs normally in the central nervous system, where immune cells are activated to maintain brain functions and counteract disease. When this process becomes unbalanced, neurological impairment occurs, as seen in conditions such as hyperammonemia and hepatic encephalopathy. These conditions cause, among other symptoms, confusion, fatigue, dizziness, impaired coordination and cognition, which have a significant negative impact on the quality of life of the affected person. Treatments that specifically limit harmful neuroinflammation are therefore desirable.
Using a preclinical disease model that induces neuroinflammation, image analyses showed that activation of immune cells in the cerebellum – the brain area that controls movement and coordination – was attenuated by treatment with golexanolone, compared to a control group. Further analyses showed that locomotion and coordination were normalised after treatment with golexanolone. In conclusion, the results indicate that harmful neuroinflammation and disease-related motor symptoms could be alleviated by correcting GABAA receptor activity with golexanolone.
"We are pleased with Umecrine Cognition's continued progress and are positive to the continued mapping of golexanolone's mechanism of action. The results indicate that golexanolol may be of great importance as a future treatment for inflammatory diseases of the CNS," said
For further information, please contact:
Phone: +46 73 982 52 02, e-mail: viktor.drvota@karolinskadevelopment.com
Johan Dighed, General Counsel and Deputy CEO,
Phone: +46 70 207 48 26, e-mail: johan.dighed@karolinskadevelopment.com
TO THE EDITORS
About
The Company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network.
For more information, please visit www.karolinskadevelopment.com.
Attachment
- KD UC prekliniska resultat neuroinflammation eng
© OMX, source
